Nature Communications (Aug 2016)
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
- Christopher A. Miller,
- Yevgeniy Gindin,
- Charles Lu,
- Obi L Griffith,
- Malachi Griffith,
- Dong Shen,
- Jeremy Hoog,
- Tiandao Li,
- David E. Larson,
- Mark Watson,
- Sherri R Davies,
- Kelly Hunt,
- Vera J. Suman,
- Jacqueline Snider,
- Thomas Walsh,
- Graham A. Colditz,
- Katherine DeSchryver,
- Richard K. Wilson,
- Elaine R. Mardis,
- Matthew J. Ellis
Affiliations
- Christopher A. Miller
- McDonnell Genome Institute, Washington University School of Medicine
- Yevgeniy Gindin
- McDonnell Genome Institute, Washington University School of Medicine
- Charles Lu
- McDonnell Genome Institute, Washington University School of Medicine
- Obi L Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Malachi Griffith
- McDonnell Genome Institute, Washington University School of Medicine
- Dong Shen
- McDonnell Genome Institute, Washington University School of Medicine
- Jeremy Hoog
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Tiandao Li
- McDonnell Genome Institute, Washington University School of Medicine
- David E. Larson
- McDonnell Genome Institute, Washington University School of Medicine
- Mark Watson
- Department of Pathology and Immunology, Washington University School of Medicine
- Sherri R Davies
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Kelly Hunt
- Department of Breast Surgery, MD Anderson Cancer Center
- Vera J. Suman
- Alliance Statistics and Data Center, Mayo Clinic
- Jacqueline Snider
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Thomas Walsh
- Department of Surgery, Division of Public Health, St Louis Breast Tissue Registry, Washington University School of Medicine
- Graham A. Colditz
- Siteman Cancer Center, Washington University School of Medicine
- Katherine DeSchryver
- Department of Medicine, Division of Oncology, Washington University School of Medicine
- Richard K. Wilson
- McDonnell Genome Institute, Washington University School of Medicine
- Elaine R. Mardis
- McDonnell Genome Institute, Washington University School of Medicine
- Matthew J. Ellis
- McDonnell Genome Institute, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/ncomms12498
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 10
Abstract
Aromatase inhibitors are used to treat oestrogen-receptor-positive breast cancer. Here, the authors use genomic approaches to analyse tumours before and after neo-adjuvant treatment and find that treatment alters the clonal landscape of the tumours.
